Tag: Isentress

According to the CDC, post-exposure prophylaxis (PEP) can reduce the risk of HIV infection by more than 80% when taken correctly. To achieve this, PEP involves a combination of powerful antiretroviral drugs that must be started within 72 hours of a potential exposure. Understanding what drugs are part of PEP is the first step in seeking this emergency prevention method.

First approved by the FDA in 2007, Isentress was the pioneering integrase inhibitor developed to treat HIV-1 infection. The medication, also known by its generic name raltegravir, is a crucial part of combination antiretroviral therapy (ART) and is used for both treatment-naive and treatment-experienced patients.